Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)

<table>Changes in OABSS in the short-term analysis set. The endpoint is presented as a mean ± standard deviation. Intragroup comparison (versus the end of the observation period) by Wilcoxon test, <svg height="15.4375" id="M52" style="vertical-align:-3.13504pt" version="1.1" viewbox="0 0 84.349998 15.4375" width="84.349998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,15.4375)">
<g transform="translate(72,-59.65)">
<text transform="matrix(1,0,0,-1,-69.87,67.83)">
<tspan style="font-size: 8.75px; " x="0" y="0">∗</tspan>
<tspan style="font-size: 8.75px; " x="4.5772958" y="0">∗</tspan>
<tspan style="font-size: 8.75px; " x="9.1545916" y="0">∗</tspan>
</text>
<text transform="matrix(1,0,0,-1,-55.64,61.87)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
<tspan style="font-size: 12.50px; " x="10.9" y="-0.95999998">&lt;</tspan>
<tspan style="font-size: 12.50px; " x="22.94039" y="-0.95999998">0</tspan>
<tspan style="font-size: 12.50px; " x="29.191889" y="-0.95999998">.</tspan>
<tspan style="font-size: 12.50px; " x="32.317638" y="-0.95999998">0</tspan>
<tspan style="font-size: 12.50px; " x="38.569138" y="-0.95999998">0</tspan>
<tspan style="font-size: 12.50px; " x="44.820641" y="-0.95999998">1</tspan>
</text>
</g>
</g>
</svg>. Intergroup comparison by Mann-Whitney <i>U</i> test, NS: not significant.</table>

Advances in Urology

fig3

Figure 3

Figure 3: Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) 

Figure 3 | Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) 